PODD - Insulet Corporation
| Previous Close | 82.72 |
| Open | 83.03 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 800 |
| Day's Range | 80.48 - 85.29 |
| 52 Week Range | 70.80 - 108.91 |
| Volume | 1,510,741 |
| Avg. Volume | 696,041 |
| Market Cap | 4.9B |
| Beta (3Y Monthly) | 1.12 |
| PE Ratio (TTM) | 1,642.60 |
| EPS (TTM) | 0.05 |
| Earnings Date | May 2, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 104.87 |
- Investor's Business Daily•4 days ago
A Diabetes Treatment Revolution Could Bolster These Medtech Firms
Medical device companies like Abbott, Medtronic and Tandem Diabetes are jockeying for a piece of the diabetes treatment market, which could be worth north of $2 trillion by 2030.
- Motley Fool•8 days ago
3 Top Diabetes Stocks to Watch in April
Find out why our team of healthcare experts is laser-focused on these diabetes stocks right now.
- Markit•13 days ago
See what the IHS Markit Score report has to say about Insulet Corp.
Insulet Corp NASDAQ/NGS:PODDView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is high * Economic output in this company's sector is expanding Bearish sentimentShort interest | NegativeShort interest is high for PODD with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting PODD. However, the last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold PODD had net inflows of $2.89 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Business Wire•18 days ago
Insulet to Announce First Quarter 2019 Financial Results on May 2, 2019
Insulet Corporation (PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced plans to release its financial results for the first quarter of 2019 on May 2, 2019 after the close of the financial markets. You may also access the live call by dialing (844) 831-3022 for domestic callers or (315) 625-6887 for international callers, passcode is 8408719. Insulet Corporation (PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to making the lives of people with diabetes and other conditions easier through the use of its Omnipod product platform.
- Zacks•26 days ago
Why Is Insulet (PODD) Up 5.1% Since Last Earnings Report?
Insulet (PODD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Motley Fool•last month
3 Top Healthcare Stocks to Buy in March
Find out why our Motley Fool contributors called out these three businesses as top opportunities right now.
Motley Fool•2 months agoWhy Diabetes Stock Insulet Jumped 15.7% in February
The leader in tubeless insulin pump technology acheived full-year profitability for the first time in 2018.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of PODD earnings conference call or presentation 25-Feb-19 9:30pm GMT
Q4 2018 Insulet Corp Earnings Call
- Simply Wall St.•2 months ago
How Do Insulet Corporation’s (NASDAQ:PODD) Returns Compare To Its Industry?
Today we'll evaluate Insulet Corporation (NASDAQ:PODD) to determine whether it could have potential as an investment idea. Specifically, we're going to calculate its Return On Capital Employed (ROCE), in theRead More...
- Zacks•2 months ago
Insulet (PODD) Beats Earnings and Revenue Estimates in Q4
The year-over-year improvement in Insulet's (PODD) Q4 results on solid uptake of Omnipod system in the United States is encouraging. The company also gains from direct European operations.
Motley Fool•2 months agoInsulet Posts Positive Earnings for the Second Consecutive Quarter
In the fourth quarter, the tubeless insulin pump specialist grew revenue 26% year over year.
Motley Fool•2 months agoInsulet (PODD) Q4 2018 Earnings Conference Call Transcript
PODD earnings call for the period ending December 31, 2018.
- Business Wire•2 months ago
Insulet Reports Fourth Quarter 2018 Revenue of $164.9 Million, Up 26% Year-Over-Year, and Full Year 2018 Revenue of $563.8 Million, Up 22%
Insulet Corporation , the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System , today announced financial results for the three months and full year ended December 31, 2018.
- ACCESSWIRE•2 months ago
Insulet Corporation to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 25, 2019 / Insulet Corporation (NASDAQ: PODD ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on February 25, 2019 at 4:30 ...
- Business Wire•2 months ago
Insulet to Present at Upcoming Investor Conferences
Insulet Corporation , the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced that management wil
- Zacks•2 months ago
Insulet (PODD) Reports Next Week: Wall Street Expects Earnings Growth
Insulet (PODD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Motley Fool•2 months ago
3 Top Diabetes Stocks to Watch in February
Innovative insulin pumps and promising drugs make these three companies worthy of investors' attention.
GuruFocus.com•2 months agoMariko Gordon's Top 5 New Buys for the 4th Quarter
Daruma Capital Management leader Mariko Gordon (Trades, Portfolio) disclosed she established seven new positions when she released her fourth-quarter 2018 portfolio earlier this week. Warning! GuruFocus has detected 1 Warning Sign with TNDM. Based on these criteria, Gordon's top five new buys for the quarter were Tandem Diabetes Care Inc. (TNDM), Macom Technology Solutions Holdings Inc. (MTSI), Insulet Corp. (PODD), LHC Group Inc. (LHCG) and Cloudera Inc. (CLDR).
- GlobeNewswire•2 months ago
Market Trends Toward New Normal in IHS Markit, KB Home, Insulet, Booking, Diebold Nixdorf, and Seritage Growth Properties — Emerging Consolidated Expectations, Analyst Ratings
NEW YORK, Feb. 07, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Business Wire•3 months ago
Insulet Appoints Corinne Nevinny to Board of Directors
Insulet Corporation (PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced that Corinne Nevinny has been appointed to the Company’s Board of Directors, effective immediately. Ms. Nevinny replaces James Mullen, who is stepping down from Insulet’s Board to focus on his family’s philanthropic foundation and other business ventures. Ms. Nevinny is the General Partner of LMNVC, a seed venture fund making early-round investments in start-up companies that have products or services that improve quality of life, including health and wellness oriented businesses.
- Business Wire•3 months ago
Insulet to Announce Fourth Quarter and Full Year 2018 Financial Results on February 25, 2019
Insulet Corporation (PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced plans to release its financial results for the fourth quarter and full year of 2018 on February 25, 2019 after the close of the financial markets. You may also access the live call by dialing (844) 831-3022 for domestic callers or (315) 625-6887 for international callers, passcode is 7262247. Insulet Corporation (PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to making the lives of people with diabetes and other conditions easier through the use of its Omnipod product platform.
- ACCESSWIRE•3 months ago
Today's Research Reports on Trending Tickers: Tandem Diabetes Care and Insulet Corporation
NEW YORK, NY / ACCESSWIRE / January 25, 2019 / U.S. equities were mixed on Thursday as stronger-than-expected quarterly earnings werent enough to outweigh concerns of a global economic slowdown. The Dow ...
